Canine Transitional Cell Carcinoma Cell Line (KU-CTCC-002)

The KU-CTCC-002 cell line, originating from an 11-year-old Maltese dog’s TCC tumor, carries the BRAF V595E mutation, underscoring its relevance in BRAF-targeted therapeutic research. It demonstrates MAPK pathway activation and a distinct response to BRAF inhibitors, with sorafenib showing pronounced efficacy over vemurafenib. The cell line’s proliferation rate and tumorigenic ability, particularly its rapid tumor growth in xenograft models, highlight its utility in exploring cancer progression, drug resistance, and the evaluation of novel therapeutic agents for both canine and comparative oncology.Note: KU-CTCC-002 grows faster than KU-CTCC-001 (Cat. T8165) and KU-CTCC-001-LM3 (Cat. T8167) in xenograft models, suggesting it may offer unique insights into tumor growth dynamics and interaction with the microenvironment. It represents a separate patient origin, providing an opportunity to study inter-tumoral heterogeneity.Complete list of cell lines from this panel:Cat. T8165 – Canine Transitional Cell Carcinoma Cell Line (KU-CTCC-001)Cat. T8166 – Canine Transitional Cell Carcinoma Cell Line (KU-CTCC-002)Cat. T8167 – Canine Lymph Node Metastasis TCC Cell Line (KU-CTCC-001-LM3)